DBV Technologies | DBVT - Selling And Administration Expenses


DBV Technologies reported $3.63M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amarin USD 18.97M 1.03M Dec/2025
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
DBV Technologies USD 3.63M 3.18M Sep/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
Galectin Therapeutics USD 1.48M 110K Jun/2024
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
Insmed USD 247.26M 34.78M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026